Risk and Management of Patients with Cancer and Heart Disease
Abstract Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart f...
Main Authors: | Loreena Hill, Bruno Delgado, Ekaterini Lambrinou, Tara Mannion, Mark Harbinson, Claire McCune |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-02-01
|
Series: | Cardiology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40119-023-00305-w |
Similar Items
-
Surveillance cardiopulmonary exercise testing can risk-stratify childhood cancer survivors: underlying pathophysiology of poor exercise performance and possible room for improvement
by: Takeshi Tsuda, et al.
Published: (2023-11-01) -
Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know
by: Armando Ferrera, et al.
Published: (2023-05-01) -
Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
by: Marina V. Vitsenya, et al.
Published: (2023-09-01) -
Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy
by: Claire Fraley, et al.
Published: (2021-09-01) -
Cardioprotective effect of thiotriazoline in cancer patients
by: A. V. Koltsov, et al.
Published: (2023-02-01)